ATTR Cardiomyopathy Drug Approved
The US FDA approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) for the treatment of wild-type or hereditary transthyretin amyloid (ATTR) cardiomyopathy based on a trial that showed a significant reduction in mortality, cardiovascular hospitalizations, and in decline in functional capacity and quality of life. The multicenter, international, double-blind, placebo-controlled, phase […]